Novo Nordisk updates DKK 15B share buyback

Novo Nordisk A/S provides an update on its ongoing share repurchase programme.

Rhea-AI Filing Summary

Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company is running a broader plan to buy back up to DKK 15 billion of B shares over 12 months beginning 4 February 2026. Within this, a specific programme started on 6 May 2026 allows repurchases of B shares up to DKK 11,200,000,010.45 through 1 February 2027.

Since the 26 May 2026 update, Novo Nordisk repurchased several B-share blocks, bringing accumulated repurchases under the current programme to 3,130,000 B shares with a total transaction value of DKK 913,270,696. As of 29 May 2026, since 4 February 2026 the company has bought back 17,889,179 B shares at an average price of DKK 263.47, for DKK 4,713,270,686 in total. Novo Nordisk now holds 35,074,480 B shares as treasury shares, equal to 0.8% of its 4,465,000,000 total A and B shares.

Key Figures

Overall buyback capacity: DKK 15 billion May 2026 sub-programme limit: DKK 11,200,000,010.45 Shares under current programme: 3,130,000 B shares +5 more

8 metrics

Overall buyback capacity DKK 15 billion Total B-share repurchase plan over 12 months from 4 February 2026

May 2026 sub-programme limit DKK 11,200,000,010.45 Maximum B-share repurchases from 6 May 2026 to 1 February 2027

Shares under current programme 3,130,000 B shares Accumulated repurchases under the programme initiated 6 May 2026

Current programme value DKK 913,270,696 Total transaction value accumulated under the May 2026 programme

Total shares since Feb 2026 17,889,179 B shares Repurchased from 4 February 2026 to 29 May 2026

Average repurchase price DKK 263.47 per B share Average price for 17,889,179 B shares repurchased since 4 February 2026

Total repurchase value DKK 4,713,270,686 Value of B shares bought back since 4 February 2026

Treasury share position 35,074,480 B shares (0.8%) Treasury B shares as a share of 4,465,000,000 total A and B shares

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, Regulation No 596/2014, +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 35,074,480 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"in accordance with ... the Commission Delegated Regulation (EU) 2016/1052 ... (the "Safe Harbour Rules")"

Regulation No 596/2014 regulatory

"in accordance with Article 5 of Regulation No 596/2014 of the European Parliament"

Commission Delegated Regulation (EU) 2016/1052 regulatory

"and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share buyback programme did Novo Nordisk (NVO) outline in this 6-K?

Novo Nordisk described a 12-month B-share repurchase plan of up to DKK 15 billion, running from 4 February 2026. Within this, a specific sub-programme began 6 May 2026 with its own B-share limit.

How much has Novo Nordisk (NVO) repurchased under the current programme?

Under the programme initiated on 6 May 2026, Novo Nordisk has repurchased 3,130,000 B shares for a total transaction value of DKK 913,270,696. These figures include purchases reported between 26 and 29 May 2026.

What is the total buyback activity by Novo Nordisk (NVO) since February 2026?

From 4 February 2026 to 29 May 2026, Novo Nordisk repurchased 17,889,179 B shares at an average price of DKK 263.47, resulting in a total transaction value of DKK 4,713,270,686.

How many treasury shares does Novo Nordisk (NVO) currently hold?

Following the reported transactions, Novo Nordisk holds 35,074,480 B shares of DKK 0.10 as treasury shares. This represents 0.8% of the company’s total A and B share capital of 4,465,000,000 shares.

What is the maximum size of Novo Nordisk’s current May 2026 buyback sub-programme?

The B-share repurchase programme that started on 6 May 2026 allows Novo Nordisk to buy back shares for an amount up to DKK 11,200,000,010.45. The programme is scheduled to run until 1 February 2027.

Where can investors find detailed daily buyback data for Novo Nordisk (NVO)?

Novo Nordisk states that detailed information for each share repurchase transaction conducted under the programme is published on novonordisk.com. Investors can review daily volumes, prices, and dates there for transparency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 07:53 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

June 1, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 1 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 26 May 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	2,289,849		670,560,306
26 May 2026	210,000	288.13	60,506,846
27 May 2026	209,971	286.16	60,085,467
28 May 2026	210,180	287.85	60,500,695
29 May 2026	210,000	293.42	61,617,382
Accumulated under the programme	3,130,000		913,270,696

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 35,074,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12month period beginning 4 February 2026. As of 29 May 2026, Novo Nordisk has since 4 February 2026 repurchased a total 17,889,179 B shares at an average share price of DKK 263.47 per B share equal to a transaction value of DKK 4,713,270,686.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. 

Contacts for further information

Media:
Ambre James-Brown		Liz Skrbkova (US)
+45 3079 9289		+1 609 917 0632
globalmedia@novonordisk.com		lzsk@novonordisk.com
Investors:
Michael Novod		Jacob Martin Wiborg Rode
+45 3075 6050		+45 3075 5956
nvno@novonordisk.com		jrde@novonordisk.com
Max Ung		Sina Meyer
+45 3077 6414		+45 3079 6656
mxun@novonordisk.com		azey@novonordisk.com
Alex Bruce		Christoffer Sho Togo Tullin
+45 34 44 26 13		+45 3079 1471
axeu@novonordisk.com		cftu@novonordisk.com
Frederik Taylor Pitter		Mads Berner Bruun
+1 609 613 0568		+45 3075 2936
fptr@novonordisk.com		mbbz@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 36 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 1, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer